NKTX Long Call Strategy
NKTX (Nkarta, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
NKTX (Nkarta, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $218.1M, a beta of 0.89 versus the broader market, a 52-week range of 1.63-3.65, average daily share volume of 822K, a public-listing history dating back to 2020, approximately 157 full-time employees. These structural characteristics shape how NKTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.89 places NKTX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long call on NKTX?
A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.
Current NKTX snapshot
As of May 15, 2026, spot at $2.67, ATM IV 111.60%, IV rank 37.71%, expected move 31.99%. The long call on NKTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this long call structure on NKTX specifically: NKTX IV at 111.60% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 31.99% (roughly $0.85 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NKTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on NKTX should anchor to the underlying notional of $2.67 per share and to the trader's directional view on NKTX stock.
NKTX long call setup
The NKTX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NKTX near $2.67, the first option leg uses a $2.67 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NKTX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NKTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.67 | N/A |
NKTX long call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.
NKTX long call payoff curve
Modeled P&L at expiration across a range of underlying prices for the long call on NKTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long call on NKTX
Long calls on NKTX express a bullish thesis with defined risk; traders use them ahead of NKTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
NKTX thesis for this long call
The market-implied 1-standard-deviation range for NKTX extends from approximately $1.82 on the downside to $3.52 on the upside. A NKTX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current NKTX IV rank near 37.71% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on NKTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, NKTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NKTX-specific events.
NKTX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NKTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NKTX alongside the broader basket even when NKTX-specific fundamentals are unchanged. Long-premium structures like a long call on NKTX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current NKTX chain quotes before placing a trade.
Frequently asked questions
- What is a long call on NKTX?
- A long call on NKTX is the long call strategy applied to NKTX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With NKTX stock trading near $2.67, the strikes shown on this page are snapped to the nearest listed NKTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NKTX long call max profit and max loss calculated?
- Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the NKTX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 111.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NKTX long call?
- The breakeven for the NKTX long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NKTX market-implied 1-standard-deviation expected move is approximately 31.99%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long call on NKTX?
- Long calls on NKTX express a bullish thesis with defined risk; traders use them ahead of NKTX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
- How does current NKTX implied volatility affect this long call?
- NKTX ATM IV is at 111.60% with IV rank near 37.71%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.